Ramucirumab plus docetaxel after combination chemoimmunotherapy in patients with non-small cell lung cancer: A prospective observational study

被引：0
|
作者：
Yamada, T. [1 ]
Katayama, Y. [2 ]
Watanabe, S. [3 ]
Watanabe, K. [4 ]
Takeda, T. [5 ]
Chihara, Y. [6 ]
Shiotsu, S. [7 ]
Hibino, M. [8 ]
Harada, T. [9 ]
Takayama, K. [1 ]
机构：
[1] Kyoto Prefectural Univ Med, Pulm Med, Kyoto, Japan
[2] Kyoto Prefectural Univ Med, Resp, Kyoto, Japan
[3] Niigata Univ Med & Dent Hosp, Dept Resp Med & Infect Dis, Niigata, Japan
[4] Tokyo Metropolitan Canc & Infect Dis Ctr Komagome, Thorac Oncol & Resp Med Dept, Bunkyo Ku, Tokyo, Japan
[5] Japanese Red Cross Kyoto Daini Hosp, Resp Med, Kyoto, Japan
[6] Uji Tokushukai Med Ctr, Resp Med, Uji, Japan
[7] Kyoto First Red Cross Hosp Kyoto Daiichi Sekijyuj, Oncol, Kyoto, Japan
[8] Shonan Fujisawa Tokushukai Hosp, Resp Med, Fujisawa, Kanagawa, Japan
[9] Fukuchiyama City Hosp, Med Oncol, Fukuchiyama, Japan
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.608
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
529P
引用
收藏
页码：S1676 / S1676
页数：1
相关论文
共 50 条
  • [41] Combination chemotherapy with docetaxel and carboplatin for advanced non-small cell lung cancer
    Schuette, W
    Bork, I
    Wollschläger, B
    Schädlich, S
    CLINICAL DRUG INVESTIGATION, 2001, 21 (03) : 161 - 168
  • [42] Phase I study of docetaxel plus S-1 combination chemotherapy for recurrent non-small cell lung cancer
    Fujitaka, Kazunori
    Hattori, Noboru
    Senoo, Tadashi
    Iwamoto, Hiroshi
    Ohshimo, Shinichiro
    Kanehara, Masashi
    Ishikawa, Nobuhisa
    Haruta, Yoshinori
    Murai, Hiroshi
    Kohno, Nobuoki
    ONCOLOGY LETTERS, 2011, 2 (01) : 167 - 170
  • [43] Detection of factors related to treatment reduction in docetaxel and ramucirumab for non-small cell lung cancer treatment
    Saito, Yoshitaka
    Tamaki, Shinya
    Hirate, Daisuke
    Takada, Shinya
    Takahashi, Kenta
    Takekuma, Yoh
    Sakakibara-Konishi, Jun
    Shimizu, Yasushi
    Kinoshita, Ichiro
    Sugawara, Mitsuru
    SCIENTIFIC REPORTS, 2023, 13 (01):
  • [44] Effect of baseline anemia on the efficacy of docetaxel and ramucirumab for advanced non-small cell lung cancer treatment
    Saito, Yoshitaka
    Takekuma, Yoh
    Sakakibara-Konishi, Jun
    Shimizu, Yasushi
    Kinoshita, Ichiro
    Sugawara, Mitsuru
    BMC CANCER, 2024, 24 (01)
  • [45] Cisplatin plus docetaxel combination in the first-line treatment of metastatic non-small cell lung cancer
    Kaya, Ali Osman
    Buyukberber, Suleyman
    Dane, Faysal
    Isikdogan, Abdurrahman
    Ustaalioglu, Basak Oven
    Coskun, Ugur
    Yumuk, Perran Fulden
    Dogu, Gamze Gokoz
    Ozdemir, Nuriye Yildirim
    Sevinc, Alper
    Gumus, Mahmut
    Ozkan, Metin
    Yildiz, Ramazan
    Ozturk, Banu
    Yaman, Emel
    Benekli, Mustafa
    TUMORI JOURNAL, 2010, 96 (03): : 400 - 404
  • [46] Multicenter, randomized study of Docetaxel versus Docetaxel plus Oblimersen in patients previously treated for non-small cell lung cancer (NSCLC)
    Herbst, Roy S.
    Ansari, Rafat H.
    Gorbunova, V
    Manikhas, G.
    Mansoor, N. Boyd
    Thomas, E.
    Azzoli, Christopher G.
    Robert, Francisco
    Itri, Loretta M.
    Chapman, Robert
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S335 - S335
  • [47] Treatment outcomes by histology in REVEL: A randomized phase III trial of Ramucirumab plus docetaxel for advanced non-small cell lung cancer
    Paz-Ares, Luis G.
    Perol, Maurice
    Ciuleanu, Tudor-Eliade
    Kowalyszyn, Ruben Dario
    Reck, Martin
    Lewanski, Conrad R.
    Syrigos, Konstantinos
    Arrieta, Oscar
    Prabhash, Kumar
    Park, Keunchil
    Pikiel, Joanna
    Goksel, Tuncay
    Lee, Pablo
    Zimmermann, Anna
    Carter, Gebra Cuyun
    Alexandris, Ekaterine
    Garon, Edward B.
    LUNG CANCER, 2017, 112 : 126 - 133
  • [48] Detection of factors related to treatment reduction in docetaxel and ramucirumab for non-small cell lung cancer treatment
    Yoshitaka Saito
    Shinya Tamaki
    Daisuke Hirate
    Shinya Takada
    Kenta Takahashi
    Yoh Takekuma
    Jun Sakakibara-Konishi
    Yasushi Shimizu
    Ichiro Kinoshita
    Mitsuru Sugawara
    Scientific Reports, 13 (1)
  • [49] Docetaxel plus ramucirumab with primary prophylactic pegylated-granulocyte-colony stimulating factor for pretreated non-small cell lung cancer
    Harada, D.
    Hata, A.
    Okuda, C.
    Kaji, R.
    Masuda, Y.
    Takechi, Y.
    Kozuki, T.
    Nogami, N.
    Katakami, N.
    ANNALS OF ONCOLOGY, 2018, 29
  • [50] Chemoimmunotherapy in Older Adults With Non-Small Cell Lung Cancer
    Tu, Hengjia
    Zhang, Yuzhuo
    You, Zhixuan
    JAMA ONCOLOGY, 2024, 10 (12) : 1732 - 1732
12345